Daratumomab interference with pre-transfusion examination of patients with multiple myeloma
10.13303/j.cjbt.issn.1004-549x.2021.04.016
- VernacularTitle:达雷妥尤单抗影响多发性骨髓瘤患者输血前检查的处理方案
- Author:
Yi WU
1
;
Shujun WANG
1
;
Wei WANG
1
;
Wen TANG
1
;
Pingping MAO
1
;
Lu WANG
1
;
Qing QI
1
;
Jianfeng LUAN
1
Author Information
1. Department of Blood Transfusion Medicine, East Military Region General Hospital, Nanjing 210002, China
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
daratumomab;
crossmatch;
dithiothreitol;
coombs' test;
polybrene method
- From:
Chinese Journal of Blood Transfusion
2021;34(4):389-392
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To solve daratumomab interference with blood compatibility testing in multiple myeloma (MM) patients treated by daratumomab(DARA). 【Methods】 The irregular antibodies screening before and after the DARA treatment, and the major side crossmatch via coombs' test and polybrene method, respectively, were performed to resolve the nonspecific interference in a MM patient’s cross-matching test, produce by DARA. 【Results】 The initial panreactivity on the major side with agglutination (3+ ~4+ ), produce by DARA, was overcome by dithiothreitol (DTT) treatment, and turner out to be none agglutination. Otherwise, DARA had no effect on the crossmatch using polybrene method. 【Conclusion】 Antibody screening and identification should be conducted before DARA treatment in MM patients, and DARA interference with blood compatibility testing can be resolved by DTT treatment or the crossmatch using polybrene method.
